Anavex initiates placebo-controlled U.S. Phase 2 trial of ANAVEX3-71

Anavex Life Sciences announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX3-71 for the treatment of schizophrenia has been screened ahead of schedule. “Initiating our Phase 2 trial of ANAVEX3-71 in schizophrenia ahead of schedule is a testament to the hard work and dedication of our clinical study team,” stated Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “Schizophrenia is a challenging disorder that can impair social and occupational functions and overall quality of life for the nearly 24 million people affected worldwide. Following on from our positive initial Phase 1 results in healthy volunteers, our Phase 2 study will apply novel neuroinflammatory, metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX3-71’s novel, dual mechanism of action, with the goal of addressing the large unmet need in this patient population. We are excited to build on our diverse Precision Medicine Platform, which advanced blarcamesine onto a regulatory pathway for potential treatment of Alzheimer’s disease.”